The AGGF1 Knockout HeLa Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal knockout cell population derived from HeLa cells, with targeted disruption of the angiogenic factor with G-patch and FHA domains (AGGF1) gene. This heterogeneous knockout pool enables loss-of-function studies of AGGF1 in a human cervical adenocarcinoma epithelial background, offering a robust tool for investigating the gene??s role in angiogenesis and tumor biology without clonal selection artifacts.
HeLa cells, originally isolated from a human cervical adenocarcinoma, are HPV18-positive and serve as a widely used cancer model system with epithelial characteristics. Their rapid proliferation, well-characterized genome, and established use in signal transduction research make them an ideal host for dissecting the contributions of AGGF1 to oncogenic and angiogenic processes. The parental line??s stable growth properties facilitate reproducible CRISPR-based knockout generation and subsequent functional assays.
AGGF1 encodes a secreted angiogenic factor containing G-patch and forkhead-associated (FHA) domains, acting upstream of critical signaling cascades. Under hypoxic conditions, AGGF1 is transcriptionally activated by HIF1A and, upon secretion, interacts with endothelial cell receptors to promote phosphorylation of AKT and ERK1/2, key downstream kinases in the PI3K/AKT and MAPK/ERK pathways. AGGF1 also undergoes homodimerization and putatively interacts with nucleic acids. By driving these signals, AGGF1 stimulates endothelial cell proliferation, migration, and capillary-like tube formation, essential steps in new blood vessel formation.
In the HeLa epithelial context, AGGF1 knockout provides a valuable model for exploring how tumor-derived angiogenic factors modulate the tumor microenvironment and influence vascularization. Since AGGF1 is implicated in vascular malformations such as Klippel-Trenaunay syndrome and in ischemic disease pathology, this knockout cell population allows researchers to dissect the tumor cell-autonomous versus paracrine contributions of AGGF1 to endothelial activation. Moreover, studying AGGF1 loss in a cancer cell line can reveal compensatory signaling mechanisms that maintain angiogenic signaling.
Typical applications include tube formation assays using conditioned media from knockout versus parental HeLa cells on endothelial cultures, transwell migration assays, and Western blot analyses of phosphorylated AKT and ERK1/2 to assess downstream pathway activity. Proliferation assays and RNA-sequencing of angiogenic gene signatures further enable comprehensive pathway analysis. Researchers investigating cancer progression, ischemic disease therapy, or vascular malformation mechanisms will find this model instrumental. For technical inquiries, please contact Ascent Research.
